TITLE

Roche cuts controversial PCR fees, testing limits

AUTHOR(S)
Anderson, C.
PUB. DATE
January 1992
SOURCE
Nature;1/30/1992, Vol. 355 Issue 6359, p379
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports that Swiss-owned pharmaceutical company Hoffmann-La Roche, under pressure from researchers and diagnostic companies, agreed to lower its prices on its polymerase chain reaction (PCR) technology and lift restrictions on its use. The move should free the technology for widespread use in testing for paternity and genetic and infectious diseases. Charges for each test; Abbott Laboratories' alternative gene amplification technique, lisage chain reaction (LCR); More.
ACCESSION #
9203093726

 

Related Articles

  • Pharmacy care Kit available from Roche.  // Drug Topics;10/10/94, Vol. 138 Issue 19, p8 

    Reports on the availability of a pharmacy counseling service from Roche Laboratories for patients on Roferon-A therapy.

  • Toradol labeling changed.  // Drug Topics;3/6/95, Vol. 139 Issue 5, p8 

    Reports on Roche Laboratories decision to change the labeling on its Toradol prescription pain reliever due to reports on side effects from improper use. Usage of the drug for pain management in postsurgical patients.

  • Program prevents pregnancies during tx.  // Dermatology Times;Sep95, Vol. 16 Issue 9, p3 

    Reports on the pregnancy prevention program conducted by Hoffman-La Roche Inc. during isotretinoin treatment for its patients.

  • La Roche lottery.  // Northern New Jersey Business;6/28/95, Vol. 3 Issue 13, p3 

    Reports on the US Food and Drug Administration's approval of the drug called Invirase, manufactured by Hoffman-La Roche.

  • Licences sought from PCR users in Britain. Dickson, David // Nature;1/28/1993, Vol. 361 Issue 6410, p291 

    Reports that genetic-screening devices throughout Britain could have their costs increase significantly as a result of claims for royalties on one of the basic laboratory techniques used in diagnostic testing, polymerase chain reaction (PCR). Recent granting of two patents on the PCR process by...

  • Roche fails to get European patent on Taq polymerase. Dickson, David // Nature;7/11/1996, Vol. 382 Issue 6587, p100 

    Reports that the European Patent Office has rejected a claim from pharmaceutical company Hoffmann-La Roche for a patent on the naturally occurring version of thermostable enzyme Taq polymerase. Use of Taq polymerase to amplify small amounts of DNA.

  • Rocephin hotline.  // Drug Topics;11/8/93, Vol. 137 Issue 21, p88 

    Announces the toll-free phone number installed by Roche Laboratories. Answering of reimbursement questions on Rocephin; Operating time.

  • Progan studies against CMV disease on hold.  // AIDS Patient Care & STDs;Oct97, Vol. 11 Issue 5, p375 

    Focuses on the Hoffman La Roche company and how he plans to stop the development of two pro-drug studies. Information on the drug and its achievements; Details on whether it could increase or eliminate the need for intravenous treatment.

  • Ciba takes lead in developing vitamin E antioxidants.  // Plastics Technology;Dec96, Vol. 42 Issue 12, p57 

    Reports on an agreement between the Additives Division of Ciba Specialty Chemicals and Hoffmann-LaRoche Incorporated, where the two companies have decided to cooperate in further development of vitamin E as a polymer stabilizer. Specifications of the agreement.

Share

Read the Article

Other Topics